- Home
- AUST vs AEON Comparison
AUST vs AEON Comparison
Compare AUST & AEON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AUST | AEON |
|---|---|---|
| Founded | 2020 | N/A |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.3M | 13.0M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | AUST | AEON |
|---|---|---|
| Price | $0.74 | $0.28 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $1.82 |
| AVG Volume (30 Days) | 52.5K | ★ 1.1M |
| Earning Date | 11-13-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.71 | $0.18 |
| 52 Week High | $3.92 | $1.45 |
Technical Indicators
Market Signals| Indicator | AUST | AEON |
|---|---|---|
| Relative Strength Index (RSI) | 32.23 | 56.22 |
| Support Level | $0.71 | $0.23 |
| Resistance Level | $1.43 | $0.33 |
| Average True Range (ATR) | 0.08 | 0.02 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 17.42 | 66.67 |
Price Performance
Historical ComparisonAbout AUST Austin Gold Corp.
Austin Gold Corp is focused on the acquisition, exploration, and evaluation of mineral resource properties in the western United States of America (USA). The exploration and development of mineral projects is considered the Company's single business segment. Its projects include Kelly Creek, Lone Mountain, Stockade Mountain, Fourmile Basin, and Miller.
About AEON AEON Biopharma Inc.
AEON Biopharma Inc is a biopharmaceutical company focused on the development of ABP-450 (prabotulinumtoxinA), a biosimilar to Botox (onabotulinumtoxinA), for therapeutic indications. The company is advancing ABP-450 through the biosimilar regulatory pathway and holds development and commercialization rights across multiple international markets.